Market research
FPH.AU Fisher & Paykel Healthcare Corporation Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 21B
- P/E ratio
- 55.02
- Analyst target
- 36.885
- Dividend yield
- 1.5%
- Beta
- 0.89
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- NZFAPE0001S2
- Market cap
- 21B
- P/E ratio
- 55.02
- Analyst target
- 36.885
- Dividend yield
- 1.5%
- Beta
- 0.89
About
About Fisher & Paykel Healthcare Corporation Limited
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, the company provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP), and nasal high flow products. Further, it offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FPH.AU discussion.
5 years, 4 months ago
Fisher & Paykel Healthcare Corporation Limited is currently in a long term downtrend where the price is trading 7.2% below its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.3.
Fisher & Paykel Healthcare Corporation Limited's total revenue rose by 59.4% to $910M since the same quarter in the previous year.
Its net income has increased by 86.1% to $226M since the same quarter in the previous year.
Finally, its free cash flow grew by 159.7% to $70M since the same quarter in the previous year.
Based on the above factors, Fisher & Paykel Healthcare Corporation Limited gets an overall score of 4/5.